Sahlgrenska Universitetsjukhuset
Gothenburg 41345
3 studies enrolling now · 11 studies all time
What they study most
Angina Pectoris, Coronary Artery Disease, Extrapulmonary Neuroendocrine Cancer (epNEC), Heart Failure With Preserved Ejection Fraction, Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease, Kidney Disease, Chronic, Lung Cancer, Non-squamous, Non-small Cell, Multiple Sclerosis, Neuroendocrine Neoplasms, Non-small Cell Lung Cancer, Pulmonary Arterial Hypertension
Studies at this site
- DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy — Recruiting now
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
- DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers — Running, not enrolling
- Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment — Running, not enrolling
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
- Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis — Completed
- A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease — Completed
- A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease — Stopped early
- A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants — Stopped early
- Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) — Completed